Physician profile
George Calloway
NPI 1033104518
$2,003.62
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $169 · 2021: $230 · 2022: $231 · 2023: $255 · 2024: $18.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $686.23 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $279.82 | 2019-2021 | |
| Abbvie INC. | $149.98 | 2021-2022 | |
| Alcon Vision LLC | $149.82 | 2022 | |
| Mdd US Operations, LLC | $141.75 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $137.56 | 2019-2021 | |
| Indivior INC. | $135.08 | 2019 | |
| Alkermes, INC. | $135.00 | 2023-2024 | Vivitrol, Vivitrol |
| Bausch & Lomb Americas INC. | $124.31 | 2023 | Vyzulta |
| Orexo US, INC. | $18.06 | 2019 | |
| Mallinckrodt Hospital Products INC. | $16.66 | 2021 | |
| Bausch Health US, LLC | $15.63 | 2021 | |
| Apellis Pharmaceuticals, INC. | $13.72 | 2023 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Calloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.